Clinical trials: TACE
Liver Cancer
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Patients with primary and secondary liver cancer may participate in this study. The purpose is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on the body (doxorubicin pharmacokinetics )…
- Trial name
- NCT02753881
- Testing
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Breast Cancer, Metastasis
Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients
The number of intervention performed for metastatic breast cancer has dramatically increased over the past 2 decades. Hepatectomy and pulmonary resection for stage IV colorectal cancer is now considered the standard of care for…
- Trial name
- IMET (NCT02251353)
- Testing
- intervention, systemic treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Federation of Breast Diseases Societies
Stage IV Melanoma Patients With Unresectable Liver Metastases
TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients
The Aim is to evaluate safety and efficacy of TACE with doxorubicin-loaded DC beads in melanoma patients with liver metastasis. This is a pilot study with the aim of recruiting 20 patients, this is a feasibility study.
- Trial name
- NCT01409733
- Testing
- TACE using Drug Eluting Beads loaded with Doxorubicin
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Liver Cancer
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the disease burden is substantial: HCC ranks fifth in cancer incidence and third in mortality, with a 5-year relative survival of only 14.4%.
- Trial name
- NCT07645209
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Harbin Medical University
Hepatocellular Carcinoma With PVTT
Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis
The treatment for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT) is still controversial, and there is no universally agreed protocol for its treatment.
- Trial name
- NCT01350206
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Small Hepatocellular Carcinoma, Stereotactic Body Radiation Therapy
Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE
The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma participants (≤5cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators…
- Conditions
- Small Hepatocellular Carcinoma, Stereotactic Body Radiation Therapy, Transcatheter Arterial Chemoembolization
- Trial name
- NCT04161287
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma
Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
Hepatectomy is still the treatment of choice for hepatocellular carcinoma. Part of the patients may present portal vein tumor thrombus (PVTT) after resection.
- Trial name
- NCT00825669
- Testing
- TACE, Laser ablation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Irradiation Stent Placement Plus TACE for HCC and PVTT
The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with…
- Trial name
- NCT03730675
- Testing
- Portal irradiation stent placement, TACE, Sorafenib
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Study introduction: this is a multicenter, randomized controlled study of patients with histopathologically confirmed hepatocellular carcinoma (HCC) who have not previously received systematic treatment for HCC, all the patients…
- Trial name
- NCT05056337
- Testing
- Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular
A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi
The 1-year and 2-year overall survival rate (OS), local control rate (FFLP), disease-free progression time (PFS), and side effects were compared in patients with hepatocellular carcinoma limited to intrahepatic unresectable…
- Trial name
- NCT03939845
- Testing
- RT, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with BCLC stage hepatocellular carcinoma (HCC).
- Trial name
- NCT02856126
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen
- Where
- 7 sites in China
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
The purpose of this study is to evaluate the safety and efficacy of the combination of donafenib and TACE in the perioperative period of liver transplantation.
- Trial name
- NCT05576909
- Testing
- Donafenib, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Unresectable Colorectal Liver Metastasis
Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis
Colorectal cancer is the third most frequently diagnosed cancer and the third leading cause of cancer related deaths in Taiwan. Of the 10,248 new colorectal patients diagnosed each year approximately 60% will develop liver…
- Trial name
- NCT03264716
- Testing
- HepaSphere TACE (transarterial chemoembolization)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC)
Multiparametric MRI for Characterization of Hepatocellular Carcinoma
This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC).
- Trial name
- NCT06999174
- Testing
- Multiparametric MRI
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- University Hospital Muenster
Liver Cancer
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Purpose: This phase II clinical trial evaluates whether a combination of liver-directed local therapies (HAIC and DEB-TACE) with immunotherapy (toripalimab) and targeted therapy (lenvatinib) is safe and effective for patients…
- Trial name
- NCT07685535
- Testing
- DEB-TACE, Toripalimab, Lenvatinib
- Volunteers
- 29 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, RFS
Postoperative Adjuvant Therapy of HCC Based on PD-1
For the treatment of hepatocellular carcinoma, liver resection is still one of the optimal options, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence…
- Trial name
- NCT05307926
- Testing
- PD-1 inhibitors, TACE
- Where
- China
- Volunteers
- 573 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma (HCC)
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
The system assesses the heterogeneity of HCC patients in terms of therapeutic outcomes (such as rwPFS, ORR, PRO) and adverse reactions during the process of interventional therapy combined with systemic treatment.
- Trial name
- NCT07156617
- Testing
- Interventional therapy, Systemic therapy
- Where
- 14 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Xuhua Duan
Lung Metastases, Endobronchial Metastases
Chemoembolization for Lung Tumors
This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
- Conditions
- Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
- Trial name
- NCT04200417
- Testing
- Chemoembolization, Mitomycin C, Lipiodol
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Recurrent
GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring
This is a prospective, multicenter, observational longitudinal study designed to evaluate the clinical performance of the GNB4 and Riplet Gene Methylation Combined Detection Kit (Real-time PCR) for monitoring recurrence after…
- Trial name
- CCGLC-019 (NCT07489768)
- Testing
- GNB4 and Riplet Gene Methylation Combined Detection Kit (Real-time PCR)
- Volunteers
- 162 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Role of DEB-TACE Versus c-TACE in Treatment of HCC
Hepatocellular carcinoma (HCC) is listed as the sixth most common cancer worldwide and the third most frequent cause of cancer-related mortality. The majority of HCC cases occurs stem from chronic liver disease and cirrhosis.
- Trial name
- NCT05093920
- Testing
- Doxorubicin-Eluting Beads
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University